Alzheimer’s Disease – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of AD comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and the diagnosed incidence of AD for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report.
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology’s AD forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with AD per year?
- How will improvements in survival change the number of people living with a diagnosis of AD?
- Of all people with AD, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with AD, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AD over the forecast period?
In addition to the total number of prevalent cases for each forecast year, Clarivate Epidemiology provides at least ten years of forecast data for the following AD subpopulations:
- Asymptomatic AD prevalent cases.
- Total MCI due to AD prevalent cases.
- Asymptomatic AD incident cases.
- Total MCI due to AD incident cases.
- Total AD incident cases.
- Diagnosed AD prevalent cases.
- Diagnosed MCI due to AD prevalent cases.
- Diagnosed AD prevalent cases by symptom status (agitation, depression, hallucinations).
- Diagnosed AD prevalent cases by severity
- Diagnosed drug-treated AD prevalent cases.
- Diagnosed drug-treated mild AD prevalent cases.
- Diagnosed drug-treated moderate AD prevalent cases.
- Diagnosed drug-treated severe AD prevalent cases.
… and many more (details available on request).
Note: Coverage may vary by country and region.
Table of contents
- Alzheimer's Disease - Epidemiology - Epidemiology Dashboard
- Introduction
- Alzheimer's Disease Epidemiology Dashboard
- Introduction
Oliver Blandy, M.Sc., is a senior epidemiologist at Clarivate. Previously, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.